4D Molecular Therapeutics
5980 Horton St. Suite 460
About 4D Molecular Therapeutics
4D Molecular Therapeutics (4DMT) is a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development.
While AAV gene therapy pioneers are making great strides with the first wave of products, hurdles still exist with the use of 1st & 2nd generation vectors (naturally occurring primitive viral capsids).
4DMT’s next-generation Therapeutic Vector Evolution platform generates targeted, optimized and proprietary AAV vectors that have the potential to overcome the delivery and immunological challenges currently facing the field, ultimately unlocking the full potential of gene therapy. We target patients with severe genetic diseases with high unmet medical need. Our discovery platform has created over 37 unique AAV vector “libraries” comprising over 100 million vectors to deliver genes specifically to any tissue/organ in the body using lower doses, with resistance to pre-existing neutralizing antibodies, and via the optimal clinical route of administration for any given disease. Additionally, our portfolio of custom capsids and intellectual property sets us apart from other companies in the AAV space. We also span a diversified pipeline and have established solid successful pharma partnerships.
The company’s lead intravitreally-delivered AAV gene therapy asset for choroideremia is expected to enter clinical trials in 2019. 4DMT closed a $90 million Series B Financing this past September with top tier investors, and their highly accomplished leadership team brings you >75 years combined experience.
Our proven team of biotherapeutics developers and innovative gene therapy scientists has highly complementary skill sets. Prior to forming 4DMT, our CEO David Kirn MD and development team members have developed over 10 different therapeutic viral vectors, including translation into the clinic and Phase 1-3 clinical development in over 30 clinical trials. Our scientists led by our CSO David Schaffer PhD were pioneers in the creation of next-generation AAV vectors for gene therapy.
We believe in success through collaboration. 4DMT has entered into multiple corporate alliances, including partnerships with Roche, Pfizer and MedImmune (AstraZeneca).
We invite all of you who share our passion and vision in creating the ultimate gene therapy products to cure genetic and rare diseases in children and adults. We seek the best people in the industry who identify with our mission and innovative results-driven approach. We offer an inspiring and collaborative environment that encourages individual contributions, recognizes performance in multiple ways, offers uniquely generous benefits and provides challenging opportunities for career development.
13 articles with 4D Molecular Therapeutics
4D Molecular Therapeutics Announces Presentation of Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update
Novel vector, 4D-C102, demonstrates superior performance compared to commonly used AAV1, AAV8, and AAV9
2/22/2019Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more.
4D Molecular Therapeutics Expands Leadership Team with Appointments and Promotions of Key Executives
4D Molecular Therapeutics, a world-leader in Therapeutic Vector Evolution for adeno-associated virus gene therapy vector discovery and product development, announced the appointments of Fred Kamal, PhD, as chief technical officer, and August Moretti as chief financial officer.
4D Molecular Therapeutics Announces Collaboration to Advance Gene Therapies for Retinal Diseases with Oregon Health & Science University’s Casey Eye Institute and Oregon National Primate Research Center
4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced a research and development collaboration with the Casey Eye Institute (CEI) and the Oregon National Primate Research Center (ONPRC) at Oregon Health & Science University (OHSU).
4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremia
4D Molecular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to 4D-110 for the treatment of choroideremia.
4D Molecular Therapeutics snagged $90 million in a Series B financing round. The company intends to use the funds to advance its Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics.
AstraZeneca’s MedImmune and 4D Molecular Therapeutics forged a collaboration to develop a gene therapy for chronic lung disease.
4D Molecular Therapeutics and MedImmune Collaborate to Design, Develop and Commercialize AAV Gene Therapy for Chronic Lung Disease
MedImmune and 4D Molecular Therapeutics announced a collaboration to develop and commercialize a gene therapeutic for patients with chronic lung disease, utilizing 4DMT’s novel discovery platform to generate optimized AAV vectors.
4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products
4D Molecular Therapeutics today announced the expansion of its 2016 research agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. into a broad long-term partnership to develop and commercialize multiple ophthalmology products.
4D Molecular Therapeutics Receives $3 Million Follow-On Funding From Cystic Fibrosis Foundation Therapeutics For Gene Therapy Ind Candidate For Cystic Fibrosis
4D Molecular Therapeutics And Foundation Fighting Blindness Partner To Develop Gene Therapies For Retinal Diseases
4D Molecular Therapeutics Enrolls First Patient In Natural History Study In Lead Clinical Program To Develop Gene Therapy Treatment For Choroideremia
Applied Genetic Technologies Corporation And 4D Molecular Therapeutics Sign Collaboration Agreement For Gene Therapy Vector Discovery And Product Development